益佰制药(600594.SH)发预亏，预计2025年度归母净亏损2.85亿元至3.42亿元

Core Viewpoint - Yibai Pharmaceutical (600594.SH) is expected to report a net loss attributable to shareholders of the parent company ranging from -342 million to -285 million yuan for the fiscal year 2025, indicating a significant downturn in financial performance [1] Financial Performance - The company's main product sales have decreased, leading to an anticipated revenue decline of 14% [1] - Although the company's cost expenses are expected to decrease by 18%, the total cost expenses will still exceed revenue, resulting in a net loss for the period [1] Impairment and Provisions - Based on preliminary impairment testing results, the financial department anticipates recognizing goodwill impairment provisions between 110 million and 132 million yuan, which will further increase the company's losses [1]